Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 4Thoracic 2Plasma cell 2Other hematologic neoplasm 2Head & Neck 2Gastrointestinal 2Dermatologic 2Sarcoma 1Myeloid 1Lymphoid 1Gynecologic 1Genitourinary 1Endocrine 1Breast 1

Conditions

Thyroid Carcinoma, Anaplastic 1Nonseminomatous germ cell tumor 1Neoplasms 1Multiple Myeloma 1Leukemia, Hairy Cell 1Glioma 1Gastrointestinal Stromal Tumors 1Biliary Tract Neoplasms 1

Interventions

entrectinib 2venetoclax 1trametinib 1tazemetostat 1sodium thiosulfate 1selpercatinib 1ripretinib 1repotrectinib 1pirtobrutinib 1pembrolizumab 1nirogacestat 1larotrectinib 1dabrafenib 1avapritinib 1atezolizumab 1Taxes 1Specimen Handling 1Rituximab 1Restraint, Physical 1Paclitaxel 1Immunoglobulin G 1Disulfides 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × trametinib × Sarcoma × Clear all
NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Novartis

Phase 2 Completed
206 enrolled 40 charts 2 FDA
CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡